# Synceres Biosciences(Shenzhen) Co

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synceres-biosciences-shenzhen-co

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.synceres.com
- Total disclosed funding: $16M
- Latest round: Series A (Jun 28, 2023)
- Investors on record: 8

## About

Based in Shenzhen, China, and founded in 2019, Synceres Biosciences(Shenzhen) Co, Ltd. operates as a biotech company focusing on the research, development, and applications of synthetic biotechnology. In May 2021, the company and Angel yeast Co., Ltd. jointly established Hubei angel senris Biotechnology Co., Ltd. The company's CEO, Mr. Xibin Zhou, signed a joint venture agreement. In June 2023, the firm raised series A+ funding from new investors Bloomage Biotechnology Corporation, Costone Venture Capital, Huayi Fund, Tasly Holding Group, Xinhenglida Capital, and Xizang Cornerstone Equity Investment Fund Management. The round was part of a larger CNY 100 million series A funding.

The company's products can be categorized into medical care, medication and solutions, skincare, nano materials, aerospace exploration materials, and bio-electronic materials. Its synthetic biology has changed the way small molecule drugs are made. It also promotes the development of cell therapy and gene therapy, and provides new methods for disease diagnosis.

## Funding rounds

- Series A, Jun 28, 2023 — CoStone Capital, New Value Capital, Bloomage Biotechnology Corporation, Tasly Holding Group, Xizang Cornerstone Equity Investment Fund Management, Huayi Fund
- Series A, Mar 16, 2022, $16M — Shenzhen HTI, Shenzhen Capital Real Estate Fund

## Investors

- Shenzhen HTI (https://capitalatlas.ai/funds/shenzhen-hti) — Series A
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A
- CoStone Capital (https://capitalatlas.ai/funds/costone-capital) — Series A
- New Value Capital — Series A
- Bloomage Biotechnology Corporation — Series A
- Tasly Holding Group — Series A
- Xizang Cornerstone Equity Investment Fund Management — Series A
- Huayi Fund — Series A